Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

ClinicalTrials.gov ID: NCT00061867

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00061867. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose Escalation, Pharmacokinetics, and Safety Study of Doxorubicin Encapsulated in Temperature Sensitive Liposomes Released Through Microwave Therapy in the Treatment of Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop tumor cells from dividing so they stop growing or die. Microwave thermotherapy kills tumor cells by heating them to several degrees above body temperature. Combining liposomal doxorubicin with microwave thermotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of liposomal doxorubicin when given together with microwave thermotherapy in treating patients with prostate cancer.

Study identification

NCT ID: NCT00061867
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Imunon; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Prostate Cancer

Interventions

pegylated liposomal doxorubicin hydrochloride Drug
hyperthermia treatment Procedure

Drug · Procedure

Eligibility (public fields only)

Age range: 40 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2003 (Type not available)
Primary completion: Not listed
Completion: Aug 2005 (Actual)
Last update posted: May 30, 2013

2003 – 2005

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Regional Urology, L.L.C.	Shreveport	Louisiana	71106	—
Grand Strand Urology LLP	Myrtle Beach	South Carolina	29572	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00061867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 30, 2013 · Synced Nov 12, 2026